Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Stavisky RC, Watson SL, Anthony MS, Manuck SB, Adams MR, Kaplan JR. Influence of estradiol on cortisol secretion in ovariectomized cynomolgus macaques (Macaca fascicularis). Am J Primatol. 2003 May;60(1):17-22.
Stavisky RC, Ayers MR, Anthony MS, Hopkins WD, Andrews M, Kaplan JR. Assessment of cognitive performance in reproductively intact and ovariectomized monkeys. Am J Primatol. 1999;49(1):103.
Williams JK, Anthony MS, Clarkson TB. Coronary heart disease in rhesus monkeys with atherosclerosis. Poster presented at the 14th Annual Meeting of the American Society of Primatologists; June 1991. Veracruz, Mexico. [abstract] Am J Primatol. 1991 Jun; 24(2):140.
Miller LC, Anthony MS, Weingand KW, Clarkson TB. Development of nonhuman primate resource for atherosclerosis research. Poster presented at the Seventh Annual Meeting, American Society of Primatologists; June 1985. Niagara Falls, NY. [abstract] Am J Primatol. 1985 Jun; 8(4):353.